Muhammad Bhatti, MD
Cardiovascular Disease · Las Vegas, NVNPI 1427047778
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,245 of the $8,011 with a category attached, or 78.0%. 23 manufacturers reported payments, led by Abbott at 46.5% of the total.
Across 154 payments — averaging $52.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$2K
- Kowa Pharmaceuticals America, Inc.$474
- Abiomed$454
- Cvrx, Inc.$259
- Boston Scientific$252
- plus $1K from 17 others
What the payments were for
- Travel & lodging$1,76622%
- Food & beverage$6,24578%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 62 | $3,722 |
| Medtronic(2 entities) | 20 | $1,549 |
| Kowa Pharmaceuticals America, Inc. | 4 | $474 |
| Abiomed | 7 | $454 |
| Cvrx, Inc. | 2 | $259 |
| Boston Scientific | 10 | $252 |
| Merck | 12 | $245 |
| Biotronik Inc. | 1 | $139 |
| Edwards Lifesciences | 1 | $131 |
| E.r. Squibb & Sons, L.L.C. | 7 | $128 |
| Lantheus Medical Imaging, Inc. | 1 | $95 |
| Pfizer | 4 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $78 |
| BD | 1 | $76 |
| Amgen | 4 | $75 |
| Shockwave Medical, Inc | 2 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Novartis | 2 | $42 |
| Itamar Medical Inc | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$1,132
- SYMPLICITY G3$626
- HawkOne$396
- Livalo$366
- Confirm Rx$297
- Barostim Neo System$259
- Impella$247
- XIENCE SIERRA$148
- COROFLOW$145
- Quadra Assura CRT Defibrillator$131
- Edwards SAPIEN 3 Transcatheter Heart Valve$131
- AMPLATZER TALISMAN$129
- CardioMEMS HF System$128
- GENERAL - THERAPIES$119
- Chocolate PTA Balloon$110
- Seglentis$108
How this compares
$8,011 in reported general payments places this provider in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 233 | $245,140 |
| EntrestoSacubitril/Valsartan | 27 | $47,326 |
| XareltoRivaroxaban | 29 | $42,007 |
| BrilintaTicagrelor | 26 | $27,359 |
| MultaqDronedarone Hcl | 12 | $13,393 |
| Amiodarone Hcl | 78 | $1,702 |
| Metoprolol Succinate | 101 | $1,341 |
| Atorvastatin Calcium | 156 | $1,309 |
| ClopidogrelClopidogrel Bisulfate | 94 | $1,150 |
| Midodrine Hcl | 12 | $1,076 |
| Bumetanide | 31 | $887 |
| Losartan Potassium | 98 | $860 |
| Metoprolol Tartrate | 144 | $830 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 34 | $721 |
| Amlodipine Besylate | 84 | $604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $245,140233 claims |
| NovartisEntresto | $42 | $47,32627 claims |
| Sanofi-aventis U.S. LLCMultaq | $57 | $13,39312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.